List of medicines under additional monitoring

  • Email
  • Help

The list of medicines under additional monitoring includes medicines authorised in the European Union (EU) that are being monitored particularly closely by regulatory authorities. Medicines under additional monitoring have a black inverted triangle displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means.

The list includes centrally and nationally authorised medicines in the following categories:

  • medicines that contain a new active substance that was not contained in any authorised medicine in the EU on 1 January 2011;
  • biological medicines authorised after 1 January 2011 - this applies to all biological medicines including biosimilars;
  • medicines for which the marketing-authorisation holder is required to carry out a post-authorisation safety study (PASS);
  • medicines given conditional approval or authorised under exceptional circumstances and medicines authorised with specific obligations on the recording or monitoring of suspected adverse drug reactions.

Summary of changes in May 2018

The following centrally-authorised products have been added to the list:

  • Alpivab (peramivir): New active substance.
  • Elebrato Ellipta (fluticasone furoate/umeclidinium/vilanterol): New active substance.
  • Juluca (dolutegravir / rilpivirine): New active substance.
  • Kanjinti (trastuzumab): New biological.
  • Mylotarg (gemtuzumab ozogamicin): New active substance and new biological.
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol): New active substance.

The following centrally-authorised products have been removed from the additional monitoring list as the condition(s) to the marketing authorisation have been fulfilled:

  • Giotrif (afatinib).
  • Ovaleap (follitropin alfa).
  • Spedra (avanafil).
  • Stribild (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil).
  • Tafinlar (dabrafenib).
  • Voncento (human coagulation factor VIII / human von Willebrand factor).

The following nationally-authorised product has been added to the list:

  • Medikinet retard 10 / 20 / 30 / 40 / 5 / 50 / 60 mg (methylphenidate hydrochloride): Post Authorisation Safety Study (PASS).

 

List of medicines under additional monitoring

Back to top

Document(s) Language Status First published Last updated Effective Date
List of medicinal products under additional monitoring (English only)   2013-04-25 2018-05-30  
List of medicinal products under additional monitoring (English only)   2013-06-23 2018-05-30  
Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union (English only)   2013-08-09 2018-03-28  
Annex I - List of cyproterone-acetate / ethinylestradiol-containing medicinal products in the European Union (English only)   2013-08-09 2018-03-28  
Annex III - List of intravenous iron-containing medicinal products in the European Union (English only)   2014-01-29 2017-11-29  
Annex III - List of intravenous iron-containing medicinal products in the European Union (English only)   2014-01-29 2017-11-29  
Annex IV - List of thiocolchicoside-containing medicinal products in the European Union (English only)   2014-01-29 2015-10-26  
Annex IV - List of thiocolchicoside-containing medicinal products in the European Union (English only)   2014-01-29 2015-10-26  
Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union (English only)   2014-01-29 2017-06-28  
Annex V - List of hydroxyethyl starch (HES)-containing medicinal products in the European Union (English only)   2014-01-29 2017-06-28  
Annex VI - List of flupirtine-containing medicinal products in the EU (English only)   2014-02-26 2017-09-27  
Annex VI - List of flupirtine-containing medicinal products in the EU (English only)   2014-02-26 2017-09-27  
Annex VII - List of Targocid and associated names (teicoplanin-containing medicinal products in the EU) (English only)   2014-02-26 2018-02-28  
Annex VII - List of Targocid and associated names (teicoplanin-containing medicinal products in the EU) (English only)   2014-02-26 2018-02-28  
Annex VIII - List of cilostazol-containing medicinal products in the European Union (English only)   2014-05-28 2017-07-26  
Annex VIII - List of cilostazol-containing medicinal products in the European Union (English only)   2014-05-28 2017-07-26  
Annex IX - List of combined hormonal contraceptives containing chlormadinone in the European Union (English only)   2014-06-25 2017-09-27  
Annex IX - List of combined hormonal contraceptives containing chlormadinone in the European Union (English only)   2014-06-25 2017-09-27  
Annex X - List of domperidone-containing medicinal products in the European Union (English only)   2014-07-30 2017-09-27  
Annex X - List of domperidone-containing medicinal products in the European Union (English only)   2014-07-30 2017-09-27  
Annex XI -List of Numeta G16%E medicinal products in the European Union (English only)   2014-09-30    
Annex XI - List of Numeta G16%E medicinal products in the European Union (English only)   2014-09-30    
Annex XII - List of Dexamed and associated names (dexamfetamine sulphate-containing medicinal products) in the European Union (English only)   2014-09-30 2017-02-22  
Annex XII - List of Dexamed and associated names (dexamfetamine sulphate-containing medicinal products) in the European Union (English only)   2014-09-30 2017-02-22  
Annex XIII - List of Valproate and related substances in the European Union (English only)   2015-01-28 2017-07-26  
Annex XIII - List of Valproate and related substances in the European Union (English only)   2015-01-28 2017-07-26